Neuroptix eyes $18.5m for Alzheimer's test
This article was originally published in Clinica
Acton, Massachusetts-based Neuroptix is to inject $18.5m it has raised in a series B financing round into the continued development of its non-invasive eye test for Alzheimer's disease. The Sapphire system works by using a non-contact optical device, combined with an eye drop to identify Alzheimer's-related proteins found in the lens of the eye. According to the company, results from preclinical testing have indicated that the amyloid-beta proteins, associated with the formation of brain plaques found in Alzheimer's patients, can be detected in the eye before they aggregate in the brain. Healthcare venture capitalist Inventages was the lead investor in the financing round.
You may also be interested in...
Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.
Roland Diggelmann will end his decade-long career at Roche Diagnostics at the end of September. The business's head of EMEA Michael Heuer will take Diggelmann's place while the search is on for his replacement.
Philips has added a new pulse oximetry platform to its patient monitoring portfolio, with the acquisition of Xhale Assurance.